ICAM1的表达促进肝癌干细胞迁移能力的研究

    The Expression of ICAM1 Promotes the Metastasis of Liver Cancer Stem Cells

    • 摘要:
      目的 本研究旨在探讨细胞间黏附分子1(intercellular adhesion molecule-1,ICAM1)在肝细胞癌(hepatocellular carcinoma,HCC)中的表达情况,并分析其表达水平与肝癌干细胞迁移能力之间的关系。
      方法 体外培养不同迁移能力的肝癌干细胞系(liver cancer stem cells,LCSC)LCSC1、LCSC2、LCSC3、LCSC4,以及肝癌细胞系HUH-7和Hep3B。利用实时荧光定量聚合酶链反应和免疫印迹筛选ICAM1高表达水平的细胞株。其次,使用Transwell实验和划痕实验评估肝癌细胞迁移能力。慢病毒转染敲低ICAM1,再次评估细胞的迁移能力。通过蛋白印记检测构建好的肝转移模型鼠体内转移灶和原发灶中ICAM1的蛋白水平。利用OSMI-1药物处理具有高迁移能力的肝癌干细胞后,使用蛋白印记和划痕实验检测细胞的ICAM1表达水平及迁移能力。
      结果 在肝癌干细胞中,ICAM1的mRNA和蛋白水平在高迁移能力和低迁移能力细胞中的表达水平,其中高迁移比低迁移的表达显著更高,且差异具有统计学意义(P<0.05)。当ICAM1被敲低后,与对照组相比,LCSC2、LCSC3、HUH-7和Hep3B细胞的迁移能力均显著降低。在小鼠肝转移模型中,ICAM1在转移灶中的表达量高于原发灶。OSMI-1药物处理后,在LCSC3和LCSC1细胞中ICAM1的蛋白表达相比于对照组降低,划痕实验结果表明药物处理后肝癌干细胞迁移能力显著降低。
      结论 ICAM1在肝癌迁移过程中高表达,ICAM1与肝癌细胞的迁移能力密切相关。敲低ICAM1后能够有效抑制LCSC2、LCSC3、HUH-7和Hep3B细胞的迁移能力。这些发现为寻找对抗肝癌干细胞迁移的潜在治疗靶点提供了重要的科学依据和新的思路。

       

      Abstract:
      Objective The aim of this study was to investigate the expression of intercellular adhesion molecule 1 (ICAM1) in human hepatocellular carcinoma (HCC) and to analyze the correlation between its expression level and the metastatic ability of liver cancer stem cells.
      Methods Human liver cancer stem cell lines LCSC1, LCSC2, LCSC3, and LCSC4 with different metastatic potentials, as well as liver cancer cell lines HUH-7 and Hep3B were cultured in vitro. Real-time fluorescence quantitative polymerase chain reaction (qPCR) and Western blot were used to detect the expression level of ICAM1 in each cell line. Transwell migration assay and wound healing assay were used to evaluate the migration ability of LCSC2, LCSC3, HUH-7, and Hep3B liver cancer cells. After knocking down ICAM1, the migration ability of LCSC2, LCSC3, HUH-7, and Hep3B cells was evaluated by Transwell migration assay. We established a liver metastasis model mouse and detected the expression level of ICAM1 in the metastatic lesions and primary lesions in mice by Western blot. After the treatment with OSMI-1 drug, the protein expression levels of ICAM1 in LCSC3 and LCSC1 cells were detected by Western blot, and the migration ability change of LCSC3 was verified by wound healing assay.
      Results In liver cancer stem cells, both mRNA and protein expression levels of ICAM1 in cells with high migration ability were significantly higher than those in cells with low migration ability, and the difference was statistically significant (P<0.05). When ICAM1 was knocked down, the migration ability of LCSC2, LCSC3, HUH-7 and Hep3B cells was significantly reduced compared with the control group. In the mouse liver metastasis model, the expression of ICAM1 in the metastatic lesion was higher than that in the primary lesion. In addition, after OSMI-1 drug treatment, the protein expressions of ICAM1 in LCSC3, LCSC1 cells were reduced compared with the control group, and the scratch test results verified significant reduction of the migration ability of liver cancer stem cells after drug treatment.
      Conclusion The high expression of ICAM1 in human liver cancer was closely related to the metastasis process of cancer cells. The knockdown of ICAM1 could effectively inhibit the metastatic ability of LCSC2, LCSC3, HUH-7 and Hep3B cells. These findings provide important scientific basis and new ideas for finding potential therapeutic targets against liver cancer stem cell metastasis.

       

    /

    返回文章
    返回